Showing posts with label ELISA. Show all posts
Showing posts with label ELISA. Show all posts

Wednesday, February 11, 2015

Proven and Published Sandwich ELISA Kits

Growing Catalog of ELISA Kits

We are partnering with RayBiotech to manufacture our ELISA Kits. They have proven valuable additions to our Cell Based Assay solutions.

Neuromics has been built on a foundation of quality. RayBiotech's commitment to quality includes compliance to GLP/GMP FDA and ISO9000 regulations.
ELISA Kits Sample Data

Figure: Induction of proinflammatory cytokines is attenuated in CX3CL1−/− mice expressing sFKN. TNFα and IL-1β concentrations were measured using standard ELISA techniques for VM lysates. a, TNFα concentrations were upregulated following MPTP administration (three-way ANOVA; F(1, 23) = 18.36, ★★★p < 0.001). Comparatively, CX3CL1−/− mice expressing sFKN in the SNpc had significantly lower concentrations of TNFα relative to mFKN (Tukey's HSD; ***p < 0.001) and GFP (Tukey's HSD; ###p < 0.001) expressing mice. There were no significant differences between sFKN and WT-MPTP (Tukey's HSD; p = 0.384) or mFKN and GFP (Tukey's HSD; p = 0.773). b, The IL-1β concentrations in the VM were significantly upregulated for mice exposed to MPTP (three-way ANOVA; F(1, 23) = 11.97, ★★★p = 0.002). Similar to the pattern of TNFα, IL-1β concentrations in CX3CL1−/− mice expressing sFKN were significantly blunted compared to both mFKN (Tukey's HSD; ***p = 0.001) and GFP (Tukey's HSD; ###p < 0.001). As was observed with TNFα, there were no significant differences in IL-1β concentrations between WT-MPTP and sFKN (Tukey's HSD; p = 0.785) or mFKN and GFP (Tukey's HSD; p = 0.845) expressing mice. Data are presented as the mean ± SEM.

Questions? Please contact me directly, Pete Shuster, CEO and Owner, 612-801-1007 or pshuster@neuromics.com. Thank you.

Monday, December 30, 2013

Autism Spectrum Disorder and Biomarkers

We used our IFN-gamma and BDNF Sandwich Elisa Kits to test the levels of these biomarkers in the blood serum of 2 individuals with Austism Spectrum Disorder. We anticipated  that BDNF would be significantly up or down regulated and IFN-gamma up regulated as confirmed by the literature. see 10.1371/journal.pone.0020470 , DOI: 10.1371/journal.pone.0020470 and DOI: 10.1111/acps.12071.

Our testing results showed:
Figure 1: ASD and Biomarker Levels

Based on these initial findings we are developing a custom Quantibody® Antibody Array designed for the fine tuned testing of individuals with ASD. The biomarkers included in the array will be: HSP70, TGF-beta2, 
Caspase-7, IFN-gamma and BDNF.

Figure 2: ASD Markers vs Controls

These panels will enable us to determine the severity of ASD. From the results, we will be working with our collaborators to determine potential cell based therapies for improving the symptom and behaviors of ASD sufferers. As part of the therapeutic regimes the panels can then be used check on progress towards "wellness". 

This a key initiative for us in 2014 so stay tuned.

Wednesday, July 23, 2008

ELISPOT

We will be releasing soon a website dedicated to ELISA and ELISpot.

Here are excellent "how to" videos.